Log ind
Genmab_logo_silver_on_green.jpg

Genmab buys antibodies from BMS

Top picks in English:

Genmab has signed a deal with US-based drug group Bristol-Myers Squibb, giving the biotech an exclusive license to an antibody panel aimed at a specific cancer target.


BY LONNI LYNGE
Offentliggjort 03.06.15 kl. 16:08

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Onxeo cleared to continue liver cancer study

Judith Greciet - Onxeo.jpg Top picks in English:

French-Danish biotech Onxeo has now received the recommendation to continue an important phase III study with its liver candidate drug Livatag. The first data from the study are expected soon.

Lundbeck sees promising phase III data on Alzheimer drug

Top picks in English:

Denmark's Lundbeck and its Japanese partner Otsuka have announced positive results from two phase III clinical trials evaluating one of their key products for the treatment of Alzheimer's disease.

Here is what Danish drug companies pay their workers

Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Danish hearing aid giants in global showdown

Top picks in English:

The world’s largest hearing device dealer, Amplifon, expresses concern over the entry into the retail market of manufacturers such as William Demant. GN Resound, on the other hand, receives praise and is expected to form even closer ties to its Italian collaborator.

Complex study delays BMS’ decision on Galecto takeover

Top picks in English:

2016 will not be the year when Denmark’s Galecto learns whether or not Bristol-Myers Squibb will buy the biotech in a multi-million-dollar deal. CEO Hans Schambye has a good gut feeling, however, nothing is set in stone in the world of biotech.

MPI test to give old chemotherapy a new lease on life

Top picks in English:

The Danish company Medical Prognosis Institute has developed a biomarker test that should revitalize a common chemotherapy drug against breast cancer. CEO Peter Buhl Jensen calls it ”the biomarker of the future.”

Forsiden lige nu

Life science-aktier på himmelfart i ferieuge

COLOURBOX2143365[1].jpg Medicinal & Biotek:

Der var markante stigninger for en lang række life science-selskaber på fondsbørsen i en uge, der blev næsten halveret af Kristi himmelfartsferien.

GSK fordobler tilbagekaldelse af astmainhalatorer

Medicinal & Biotek:

GlaxoSmithKline trækker endnu engang flere partier af en udbredt type inhalator brugt i astma- og KOL-behandling tilbage fra det amerikanske marked. Tilbagekaldelsen er nu samlet set på mere end 1,1 millioner enheder.

Forbrugere stoler mere på robotkirurger end robotrådgivere

Medico & Rehab:

Forbrugerne vil hellere have foretaget en hjerteoperation af en robot end at betro en robot opgaven at åbne en opsparingskonto, viser en undersøgelse foretaget af den britiske storbank HSBC. Det skriver Finextra.

FDA: Nye Martin Shkrelis skal stoppes, før de begynder

Medicinal & Biotek:

Den nye direktør for de amerikanske lægemiddelmyndigheder sætter gang i en række nye tiltag, der skal stoppe folk, der vil gå i Martin Shkrelis fodspor.

Beskeden salgsvækst for Medtronic i kort år

Medico & Rehab:

Medtronic har hævet sin omsætning en kende, mens bundlinjen stiger ganske pænt i et regnskabsår, der indeholdt en uge mindre end normalt.

Kandidat til brystkræftbehandling får FDA-opbakning

Medicinal & Biotek:

Et klart flertal i et ekspertpanel hos FDA anbefaler godkendelse af en ny brystkræftbehandling fra et amerikansk biotekselskab.

ANNONCE
ANNONCE


ANNONCE